Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Cor.../ US4579852082 /
IART
|
07.06.2024 22:00:00
|
Zm.
-0,3100
|
Wolumen |
Bid00:51:05 |
Ask00:51:05 |
Kapitalizacja Rynkowa |
St. dywidendy |
Wskaźnik C/Z |
|
30,8000USD
|
-1,00%
|
803 906
Obrót: 16,91 mln |
30,9500Wolumen Bid: 300 |
32,0000Wolumen Ask: 500 |
2,43 mldUSD |
- |
36,24 |
Opis działalności
Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for caregivers, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading regenerative technologies, in specialty surgical solutions and orthopedics and tissue technologies.
Zarząd & Rada nadzorcza
| CEO |
| Jan De Witte |
| Zarząd |
| Carrie Anderson, Andrea Caruso, Dr. Kenneth Burhop, Eric Schwartz, Glenn G. Coleman, Judith E. O'Grady, Lisa Evoli, Michael McBreen, Robert T. Davis Jr., Sravan K. Emany, Steve Leonard, Susan Krause, William Compton |
| Rada nadzorcza |
| Dr. Stuart M. Essig, Barbara B. Hill, Christian S. Schade, Dr. Donald E. Morel, Jr., Dr. Keith Bradley, Peter J. Arduini, Raymond G. Murphy, Rhonda Germany Ballintyn, Shaundra D. Clay |
Dane firmy
| Nazwa: |
Integra LifeSciences Holdings Corp. |
| Adres: |
1100 Campus Road,Plainsboro, New Jersey 08540, USA |
| Telefon: |
+1-609-275-0500 |
| Fax: |
+1-609-275-5363 |
| E-mail: |
custsvcnj@integralife.com
|
| Internet: |
www.integralife.com/ |
| Przemysł: |
Biotechnologia |
| Sektor: |
Biotechnologia |
| Podsektor: |
Biotechnologia |
| Koniec roku finansowego: |
31.12 |
| Free float: |
38,60% |
| Data IPO: |
- |
Relacje inwestorskie
| Nazwa: |
Michael Beaulieu |
| Telefon: |
+1-609-936-2268 |
| Fax: |
- |
| E-mail: |
ir@integralife.com
|
Główni akcjonariusze
| Freefloat |
|
38,60% |
| Tru St Partnership LP and Provco Leasing |
|
11,70% |
| Wellington Management Group LLP |
|
11,40% |
| Capital Research & Management Co. |
|
9,80% |
| The Vanguard Group |
|
7,70% |
| Champlain Investment Partners, LLC |
|
7,70% |
| BlackRock, Inc. |
|
7,60% |
| Janus Henderson Group plc 201 |
|
5,50% |
